Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dianthus Therapeutics (DNTH) EBT (2017 - 2025)

Dianthus Therapeutics has reported EBT over the past 8 years, most recently at -$38.9 million for Q3 2025.

  • Quarterly results put EBT at -$38.9 million for Q3 2025, down 40.1% from a year ago — trailing twelve months through Sep 2025 was -$127.5 million (down 72.82% YoY), and the annual figure for FY2024 was -$84.5 million, down 94.65%.
  • EBT for Q3 2025 was -$38.9 million at Dianthus Therapeutics, down from -$34.5 million in the prior quarter.
  • Over the last five years, EBT for DNTH hit a ceiling of $28.2 million in Q4 2022 and a floor of -$38.9 million in Q3 2025.
  • Median EBT over the past 4 years was -$17.9 million (2024), compared with a mean of -$16.8 million.
  • Peak annual rise in EBT hit 69.16% in 2023, while the deepest fall reached 149.33% in 2023.
  • Dianthus Therapeutics' EBT stood at $28.2 million in 2022, then crashed by 149.33% to -$13.9 million in 2023, then crashed by 77.1% to -$24.6 million in 2024, then tumbled by 58.01% to -$38.9 million in 2025.
  • The last three reported values for EBT were -$38.9 million (Q3 2025), -$34.5 million (Q2 2025), and -$29.4 million (Q1 2025) per Business Quant data.